SHORT MINI-FUTURE - BIOGEN IDEC | Delayed Deutsche Boerse AG 02:00:07 22/05/2024 pm IST | ||
| 11.6 EUR | -0.85% |
|
| Current month | -8.59% | ||
| 1 month | -22.26% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
BIOGEN INC.
Latest news about BIOGEN INC.
More news
| Date | Price | Change |
|---|---|---|
| 22/24/22 | 11.6 | -0.85% |
| 21/24/21 | 11.7 | +4.37% |
| 20/24/20 | 11.21 | -1.49% |
| 17/24/17 | 11.38 | -0.18% |
| 16/24/16 | 11.4 | +5.95% |
Delayed Quote Deutsche Boerse AG
Last update May 22, 2024 at 02:00 pm IST
More quotesStatic data
| Product type | Knock-Out with Stop Loss |
|---|---|
| Buy / Sell | PUT |
| Underlying | BIOGEN INC. |
| Issuer | 
Vontobel
|
| WKN | VX0151 |
| ISIN | DE000VX01516 |
| Date issued | 01/09/2021 |
| Strike | 352.5 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 1.27 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 15.7 € |
|---|---|
| Lowest since issue | 1.38 € |
| Spread | 0.16 € |
| Spread % | 1.36% |
Company Profile
Biogen Inc. is one of the world's leaders in the design, manufacturing, and marketing of therapeutic products. Net sales break down by source of income as follows:
- sales of medicines (73,7%): for treating multiple sclerosis, chronic psoriasis in adults, rheumatoid arthritis, cancers, etc.;
- royalties (17,2%) ;
- other (9,1%): primarily revenues from partnership agreements.
Sector
-
Consensus: Biogen Inc.
Sell
Buy
Mean consensus
BUY
Number of Analysts
34
Last Close Price
227.7
USD
Average target price
285.9
USD
Spread / Average Target
+25.57%
- Stock Market
- Certificates
- Certificat